Free weekly newsletter
Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Clendon Biotech Capital Partners with InhaleRx for $38.5 Million Funding
Oct 20, 2024•over 1 year ago
Contract Type
partnership
Biotechnology
Description
Biotechnology company InhaleRx has secured $38.5 million in funding from Clendon Biotech Capital to further develop its precision medicines delivered via inhalation. The partnership will cover all direct costs associated with the Phase 1 & 2 clinical development of its key drug development projects – IRX-211 and IRX-616a, targeting breakthrough cancer pain and panic disorder relief.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months